AzTrials
AzTrials

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromePhase 1NCT03874052

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 study testing Azacitidine, Biospecimen Collection and Bone Marrow Aspiration in people with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Recurrent Acute Myeloid Leukemia, run by Jennifer Saultz at 3 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or has not responded to… Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Azacitidine, Biospecimen Collection and Bone Marrow Aspiration
Could I receive a placebo?
No, everyone receives an active treatment
How many people
51 participants
Where
3 sitesUnited States
Study dates
16 Aug 2019to 31 Dec 2027
Phase
Phase 1

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ability to understand and the willingness to sign a written informed consent document
  • Age >= 18 years at time of informed consent. Persons of all genders and gender identities, and members of all races and ethnic groups will be included
  • Morphologically documented relapsed/refractory (R/R) AML or R/R secondary AML (sAML) that has progressed after at least 1 prior therapy for AML
  • Prior treatment with venetoclax and azacitidine is allowed
  • Treatment with hydroxyurea will not be considered a line of therapy
  • Patients with morphologically documented myelodysplastic syndrome (MDS) that has progressed on hypomethylating agent (HMA) therapy also will be considered if the patient is ineligible for induction with intensive chemotherapy (IC), defined for this study as meeting one or more of the following criteria:
Show all 19Show fewer
  • Severe cardiac disorder (e.g., congestive heart failure requiring treatment, left ventricular ejection fraction (LVEF) of ≤ 50%, or chronic stable angina)
  • Severe pulmonary disorder, certified by the managing physician
  • Creatinine clearance of < 45 ml/min or
  • Hepatic disorder with total bilirubin > 1.5 x upper limit of normal (ULN)
  • Eastern Cooperative Oncology Group (ECOG) equal to 2
  • Other comorbidity(ies) judged to be incompatible with high dose chemotherapy by the managing physician will be considered, at the discretion of the principal investigator (PI)
  • ECOG performance status 0 to 2
  • Persons of childbearing potential (PCBP) must have a negative serum or urine pregnancy test within 14 days prior to start of study drug administration
  • Patients must agree to use an adequate method of contraception while on study treatment and for 120 days after the last dose of ruxolitinib for Arm 1 and 6 months after the last dose of azacitidine for Arm 2
  • Must be able to take and absorb oral medications
  • Creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hour urine collection
  • Total serum bilirubin ≤ 1.5 x ULN unless thought to be due to leukemic involvement
  • Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≤ 3.0 x ULN unless thought to be due to leukemic involvement

Who cannot join

  • Diagnosis of acute promyelocytic leukemia (APL or AML M3 subtype)
  • Active central nervous system involvement with AML
  • Chemotherapy or therapy with a non-investigational agent other than a biologic intended to within 1 week of the planned start of study therapy, with the exception of hydroxyurea for cytoreduction of proliferative disease, or at the discretion of the principal investigator (PI)
  • Therapy with a non-biologic investigational agent within 14 days or 5 half lives, whichever is longer, of the planned start of study therapy, or for the period recommended by the institution's research pharmacy service, or at the discretion of the PI
  • Therapy with a biologic investigational or non-investigational agent (e.g., monoclonal antibody) within 30 days of the planned start of study therapy, or for the period recommended by the institution's research pharmacy service, or at the discretion of the PI
  • Concurrent active malignancy with expected survival of less than 1 year, at the discretion of the investigator. For example, candidates with treated skin cancers, prostate cancer, breast cancer, etc. without metastatic disease are candidates for therapy since their expected survival exceeds that of relapsed or refractory AML
Show all 24Show fewer
  • Clinically significant graft versus host disease (GVHD) or active GVHD requiring initiation or escalation of treatment within 28-day screening period
  • Participants with rapidly progressive disease (defined by blast count doubles within 48 hours) or organ dysfunction
  • Documented cardiac insufficiency (e.g., symptomatic heart failure, left ventricular ejection fraction of ≤ 40%)
  • Symptomatic shortness of breath or patient requires supplemental oxygen support
  • Clinically significant coagulation abnormality, such as disseminated intravascular coagulation
  • Known history of cerebrovascular accident, myocardial infarction, or intracranial hemorrhage within 2 months of enrollment
  • Known clinically significant liver disease defined as ongoing drug-induced liver injury, chronic active hepatitis C (hepatitis C virus [HCV]), chronic active hepatitis B (hepatitis B virus [HBV]), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, extrahepatic obstruction caused by cholelithiasis, cirrhosis of the liver, portal hypertension, or history of autoimmune hepatitis
  • Untreated HIV or active hepatitis C detectable by polymerase chain reaction (PCR), or chronic hepatitis B (patients positive for hepatitis B core antibody who are receiving intravenous immunoglobulin therapy [IVIG] are eligible if hepatitis B [HepB] PCR is negative)
  • Per PI discretion, active infection that is not well controlled by antibacterial or antiviral therapy
  • Patients with a known history of tuberculosis (TB; Mycobacterium tuberculosis) are not eligible for participation. At investigator discretion, latent TB test should be performed for individuals considered to be at high-risk (e.g., immune compromised, persons that have traveled to, or emigrated from, regions with high rates of TB)
  • Clinically significant surgery within 2 weeks of enrollment
  • Unwillingness to receive infusion of blood products
  • Requires use of medications interact with study drug and that cannot be terminated or adjusted. Use of the following therapies requires review by the sponsor investigator:
  • Strong and moderate CYP3A inhibitors
  • Strong and Moderate CYP3A inducers
  • Patients with uncontrolled white blood cell (WBC) count (defined as > 25 K/mm^3 and not controlled with hydroxyurea)
  • Patients with known sensitivity to ruxolitinib, venetoclax, or azacitidine
  • Since it is unknown whether ruxolitinib, venetoclax, or azacitidine (or their metabolites) are excreted in human milk and because of the potential for serious adverse reactions in the nursing infant, breastfeeding concurrent with study participation is prohibited

Trial locations and contacts

3 sites in 1 country. Contact the study team or a site near you to ask about taking part.

United States3 sites, 3 recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210

    Uma Borate, MD, 614-293-9869, uma.borate@osumc.edu

    Uma Borate, MD

    Recruiting

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas, 75390

    Meredith Pogue, 214-648-5919, Meredith.Pogue@UTSouthwestern.edu

    Yazan Madanat, MD

    Recruiting

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239

    Jennifer N. Saultz, MD, 503-494-5566, saultzje@ohsu.edu

    Jennifer N. Saultz, MD

    Recruiting

Other trials in United States

About this study

Official title: Phase I Study to Evaluate Safety of Ruxolitinib in Combination With Azacitidine + Venetoclax in Patients With Relapsed/Refractory Acute Myeloid Leukemia

This phase I trial studies the side effects and best dose of ruxolitinib when given together with venetoclax and compares the effect of ruxolitinib in combination with venetoclax to venetoclax and azacitidine in treating patients with acute myeloid leukemia (AML) that has come back (relapsed) or has not responded to treatment (refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine stops cells from making deoxyribonucleic acid and may kill cancer cells. It is a type of antimetabolite. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving ruxolitinib in combination with venetoclax and azacitidine may be safe, tolerable, and/or effective compared to ruxolitinib with venetoclax in treating patients with relapsed or refractory AML.

Read the detailed description

PRIMARY OBJECTIVE:

  1. To evaluate an maximum-tolerated dose (MTD) for ruxolitinib in combination with Ia. Venetoclax (Arm 1); Ib. Venetoclax and azacitidine (Arm 2).

SECONDARY OBJECTIVES:

  1. To assess the efficacy of the study treatment. II. To assess the duration of clinical response. III. To assess the duration of clinical benefit. IV. To assess survival in the absence of treatment failure, hematologic relapse, or progressive disease.
  2. To assess overall survival. VI. To assess overall acute toxicity and tolerability. VII. To assess the effect of ruxolitinib in combination with azacitidine + venetoclax on quality of life (QOL).

EXPLORATORY OBJECTIVES:

  1. To assess in vitro kinase inhibitor sensitivity using participants' bone marrow (or peripheral blood).

II. To characterize changes in disease using molecular techniques (potentially including next-generation sequencing and/or BH3 profiling).

III. To assess the impact of changes in molecular disease features. IV. To determine the in vivo pharmacokinetics (PK)/pharmacodynamics (PD) parameters of the study drugs (Arm 1 only).

OUTLINE: This is a dose-escalation study of ruxolitinib in combination with fixed dose venetoclax with and without azacitidine. Patients are assigned to 1 of 2 arms.

ARM 1 (COMPLETE 04/04/2025): Patients receive ruxolitinib orally (PO) twice daily (BID) and venetoclax PO once daily (QD) on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator. Patients also undergo a skin punch biopsy and echocardiography (ECHO) at screening and blood sample collection and bone marrow aspiration and biopsy throughout the study.

ARM 2: Patients receive ruxolitinib PO BID, venetoclax PO QD, and azacitidine intravenously (IV) or subcutaneously (SC) on days 1-7 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at screening and blood sample collection and bone marrow aspiration and biopsy throughout the study.

After completion of study treatment, patients are followed up every 6 months for up to 2 years.

Being tested
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography Test
Medical subject headings
Leukemia, Myeloid, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AzacitidineDrug

    Also called 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine

    Given IV or SC

  • Biospecimen CollectionProcedure or surgery

    Also called Biological Sample Collection, Biospecimen Collected, Specimen Collection

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure or surgery

    Undergo bone marrow aspiration and biopsy

  • Bone Marrow BiopsyProcedure or surgery

    Also called Biopsy of Bone Marrow, Biopsy, Bone Marrow

    Undergo bone marrow aspiration and biopsy

  • Echocardiography TestProcedure or surgery

    Also called EC, Echocardiography

    Undergo ECHO

  • Punch BiopsyProcedure or surgery

    Also called BIOPSY, PUNCH, Punch Biopsy of Skin

    Undergo skin punch biopsy

  • Questionnaire AdministrationOther

    Ancillary studies

  • RuxolitinibDrug

    Also called INCB 018424, INCB-018424, INCB-18424, INCB18424

    Given PO

  • VenetoclaxDrug

    Also called ABT 199, ABT-0199, ABT-199, ABT199

    Given PO

Study groups in NCT03874052
Study groupRoleWhat they receive
Arm 1 (ruxolitinib, venetoclax)ExperimentalPatients receive ruxolitinib PO BID and venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. Patients may receive additional cycles of ruxolitinib and venetoclax at the discretion of the sponsor-investigator. Patients also undergo a skin punch biopsy and ECHO at screening and blood sample collection and bone marrow aspiration and biopsy throughout the study. (COMPLETE 04/04/2025)
Receives: Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Echocardiography Test; Procedure: Punch Biopsy; Other: Questionnaire Administration; Drug: Ruxolitinib; Drug: Venetoclax
Arm 2 (ruxolitinib,venetoclax, azacitidine)ExperimentalPatients receive ruxolitinib PO BID, venetoclax PO QD, and azacitidine IV or SC on days 1-7 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO at screening and blood sample collection and bone marrow aspiration and biopsy throughout the study.
Receives: Drug: Azacitidine; Procedure: Biospecimen Collection; Procedure: Bone Marrow Aspiration; Procedure: Bone Marrow Biopsy; Procedure: Echocardiography Test; Procedure: Punch Biopsy; Other: Questionnaire Administration; Drug: Ruxolitinib; Drug: Venetoclax

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dose-limiting toxicities (DLT) for each arm-specific combination

    Within each arm, patient-level toxicity events will be summarized by dose level, major organ category, and grade.

    Measured: Up to day 56 (of cycle 1 [cycle length = 28 days]) for non-hematologic DLT and up to day 42 (of cycle 1 [cycle length = 28 days]) for hematologic DLTs

Secondary outcomes (9)

  1. Composite complete remission rate

    Will be estimated, along with 95% confidence intervals (CIs).

    Measured: From first dose to end of cycle 2 (cycle length = 28 days)

  2. Clinical response rate

    Will be estimated, along with 95% CIs.

    Measured: From first dose to end of cycle 2 (cycle length = 28 days)

  3. Clinical benefit rate (CBR)

    CBR will be defined as the proportion of evaluable subjects obtaining stable disease (SD), partial remission, or composite complete remission during the first 2 cycles of therapy. Will be estimated, along with 95% CIs.

    Measured: From first dose to end of cycle 2 (up to 36 days)

  4. Duration of clinical response

    Measured: From first morphologic leukemia-free state or better to bone marrow blasts >= 5%, circulating blasts, or EMD, or date of last disease assessment, assessed up to 2 years

  5. Duration of clinical benefit

    Measured: From first SD or better to evidence of progressive disease, or date of last disease assessment, assessed up to 2 years

  6. Event-free survival (EFS)

    Will be estimated using the Kaplan-Meier method, with median and survival rate estimates at common landmark times reported with 95% log-log CIs. Univariable Cox models will be fit to EFS to assess the impact of baseline patient and disease features; model results such as unadjusted hazard ratios and associated Wald test p-values will be considered hypothesis-generating.

    Measured: From first occurrence of treatment failure, disease progression, or death due to any cause, or date of last exam, assessed up to 2 years

  7. Overall survival (OS)

    Will be estimated using the Kaplan-Meier method, with median and survival rate estimates at common landmark times reported with 95% log-log CIs. Univariable Cox models will be fit to OS to assess the impact of baseline patient and disease features; model results such as unadjusted hazard ratios and associated Wald test p-values will be considered hypothesis-generating. Median follow-up (and 95% log-log CI) will utilize a patient's OS time and censoring status and be estimated using the reverse Kaplan-Meier method.

    Measured: From date of first dose to death due to any cause or date of last known alive, assessed up to 2 years

  8. Overall incidence of treatment-related and non-treatment related toxicity

    The overall incidence of treatment- related and non-treatment- related toxicity will be determined using the safety-evaluable population. The point estimate and 95% CI for the proportion of patients with each of these toxicity types will be reported. adverse event and abnormal concerning laboratory values will be tabulated by patient and by toxicity event (there can be > 1 event patient) will be tabulated overall and within dose level and summarized by major organ site and severity according to the Common Terminology Criteria for Adverse Events version 5.0.

    Measured: From first dose to 30 days after last dose of study agent

  9. Changes in patient reported quality of life (QOL) outcomes (Arm 2)

    Will be assessed using European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 and Patient Reported Outcomes Measurement Information System-Fatigue-Short Form 7A. Will be reported with descriptive statistics (e.g., sample size, median, and range) for each survey time point during the treatment period and for (within-patient) changes from baseline. The QOL summary statistics from each survey will be compared to other studies conducted in relapsed/refractory acute myeloid leukemia patients.

    Measured: From first dose of study treatment to date of last completed survey, assessed up to 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Mar 2019
  2. Study start16 Aug 2019
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Sequential
Masking
None (open label)
Enrolment
51 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03874052
Sponsor's protocol ID
STUDY00018238
Other IDs
NCI-2019-03272, STUDY00018238
Status last verified
Sep 2026
First submitted
10 Jan 2019
Last updated
24 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Borate U, Tognon CE, Madanat YF, Misra S, Kaempf A, Patel PA, Davis KL, Sun J, Stuani L, Eisenmann ED, Eide CA, Kurtz SE, Watanabe-Smith K, Johnson K, Jager A, Gullaksen SE, Robinson B, Vu T, Plevritis SK, Baker SD, Minnier J, Clement P, Avaylon S, Hayes M, Newell LF, Gandhi AP, Leonard J, Hayes-Lattin B, Vasu S, Cook RJ, Meyers G, Maziarz RT, Traer E, Swords R, Tyner JW, Druker BJ, Saultz JN. Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia. Blood Neoplasia. 2026 Feb 5;3(2):100205. doi: 10.1016/j.bneo.2026.100205. eCollection 2026 May.

    PubMed 42007254

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in